Trial Profile
A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jan 2022 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Results (n=150) published in the Gynecologic Oncology.
- 30 May 2014 Primary endpoint 'Progression-free-survival' has not been met.